|
 News
Releases
|
|
Datex-Ohmeda S/5 Telemetry System Cleared
For Marketing
NEW
YORK, Jul 14 (Reuters Health) - The US Food and
Drug Administration has cleared for marketing the
Datex-Ohmeda S/5 Telemetry System, a wireless method of
diagnosing myocardial infarction, Datex-Ohmeda said on
Thursday.
The system,
which offers 12-lead electrocardiography (ECG), was
developed jointly by the Finnish firm Datex-Ohmeda, with
US headquarters in Tewksbury, Massachusetts, and
Milwaukee-based Mortara Instrument. The product combines
Datex-Ohmeda's "patient monitoring capabilities and
Mortara's electrocardiography," the firms said.
Set to launch
later this year, the S/5 Telemetry System "is the
first...to offer the accuracy of ST analysis (an
indicator of infarction and its location) in all 12
leads," Datex-Ohmeda said. "This feature helps
doctors to diagnose the location and extent of the damage
to the heart muscle and make treatment decisions with
more accurate information than has been possible
previously," the company claims.
The system
will be one of the first devices in Datex-Ohmeda's family
of System 5 products to be introduced in North America,
the company said. The System 5 family will encompass a
range of products for five applications areas:
anesthesia, post-anesthesia care, critical care,
emergency care and transport. System 5 "is designed
to simplify the anesthesia and critical care environment
by offering the benefits of integration across the
company's range of products and services."
|
|
|
